Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin With or Without NaviFUS System in Recurrent Glioblastoma Multiforme
NCT06496971Phase 3Recruiting
- Sponsor
- NaviFUS
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sulfur hexafluoride in glioblastoma multiforme (GBM) (2 arms), sponsored by NaviFUS. Primary endpoint: 6-month progression-free survival. Started Nov 2024; status: recruiting.
02
Drugs
sulfur hexafluoride
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT06496971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496971.